Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials

A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.

(2020) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

(2020) Robin Kate Kelley et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results.

(2020) Anwaar Saeed et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.

(2020) Joel W. Neal et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study.

(2020) Sumanta K. Pal et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.

(2020) Neeraj Agarwal et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

(2015) Joong-Won Park et al.   LIVER INTERNATIONAL

FDA Approves Sorafenib for Patients With Inoperable Liver Cancer

(2008) Les Lang   GASTROENTEROLOGY